HDII.. $0.06 My take.. The Company reported a cash balance on June 30, 2010 of $1,053,648.
My take is that HDII has a favorable risk/reward level below $0.10.. Insider purchases tend make me believe that the sale of machines are ramping up and HDII now has positive non-gap earnings.. A read of the below from thier latest release tends to support favorable reaction to thier products from the medical.. When first made aware of HDII from another poster last year I made some inquirys to my doctors about the value of HDII products and while they said they were useful the ability to get Insurance reinbursmets were the question.. As they had doubt I never took a position and the stock doubled to over $0.22.. Now that HDII has demonstrated it's ability to make sales I think it qualifys for accumulation below $0.10 if any tax selling occurs.. hank
About Hypertension Diagnostics, Inc.
Hypertension Diagnostics, Inc. ("HDI") manufactures and markets medical devices for early detection and management of cardiovascular disease in the U.S. and in 37 countries. Its main product, the CVProfilor&4; DO- 2020 CardioVascular Profiling System, has been approved by the Food and Drug Administration (FDA), and is being marketed to primary care physicians in the U.S. HDI's CardioVascular Profiling Systems non-invasively measure both large and small artery elasticity. Small artery elasticity has been shown to be predictive of cardiovascular disease. Several large pharmaceutical manufacturers have used HDI's CardioVascular Profiling Systems in their multi-site clinical research trials. There are over 300 published, peer-reviewed scientific articles and presentations on HDI's methodology, which provides evidence on the validity, accuracy and reproducibility of HDI's CardioVascular Profiling technology. The technology was developed at the University of Minnesota by a team led by world-renown cardiologist, Dr. Jay N. Cohn.
Revenue for FY 2010 totaled $1,383,669 compared to $503,175 in the fiscal year ended June 30, 2009 (FY 2009), which represents a 175% increase. The Company incurred a net loss of $989,759 for FY 2010 or $(.02) per share, compared with a net loss of $248,440 for FY 2009, or $(.01) per share.
"The fourth quarter, and in particular the month of June, was a remarkable period for the Company with the highest number of units sold in any month in the Company's history," said Mark Schwartz, Chairman and CEO. "Most importantly, the Company generated cash from operations of $279,080 and therefore was profitable on a non-GAAP basis."
Included in the net loss for FY 2010 are total non-cash charges (mainly deferred stock compensation, depreciation, stock options) of $1,204,391. Included in the net loss for FY 2009 are total non-cash benefits of $125,102. The charge for FY 2010 is a result of an increase in the Company's stock price, which increased the non-cash deferred compensation. The benefit for FY 2009 is a result of a decrease in the Company's stock price, which caused the non-cash deferred compensation expense to become a non-cash benefit. The Company reported a cash balance on June 30, 2010 of $1,053,648.
Fourth quarter revenue of $497,007, for fiscal year 2010 (Q4 2010) compared to $164,691 for the fourth quarter of fiscal year 2009, represented a 202% increase. Revenue for Q4 2010 increased by 294% compared with $126,261 for the third quarter of fiscal year 2010.
The number of units sold by the Company during FY 2010 increased 225% compared with sales during FY 2009. Of those units sold, 15 were from the previously reported START study funded by the National Institutes of Health (NIH) to determine whether the measurement of elasticity can assist in the prevention of cardiovascular disease in HIV patients. Without the START study sales, unit volume increased by 150%.
In June, the Company changed its estimated inventory obsolescence allowance to more accurately reflect the shift from a rental to a sales model and better reflect the gross profit on equipment sales, resulting in an adjustment to inventory and to cost of sales of $150,614. This caused the Company to report a negative cost of sales or an increase in income for FY 2010.
AI
